1 Both the plasma endothelin-1 (ET-1) levels and the plasma glucose levels were markedly elevated in streptozotocin (STZ)-induced diabetic rats. 2 The maximum contractile response of the mesenteric arterial bed to ET-1 was signi®cantly reduced, and the vasodilatation induced by the ET B -receptor agonist IRL-1620 in the mesenteric arterial bed was signi®cantly reduced in STZ-induced diabetic rats. 3 ET-1 (10 78 M) caused a transient vasodilatation followed by a marked vasoconstriction in methoxamine-preconstricted mesenteric arterial beds. The ET-1-induced vasodilatation was signi®cantly larger in beds from diabetic rats than in those from age-matched controls. By contrast, the ET-1-induced vasoconstriction was signi®cantly smaller in STZ-induced diabetic rats than in the controls. 4 Both removal of the endothelium with Triton X-100 and preincubation with BQ-788 (10 76 M) (ET Breceptor antagonist) abolished the ET-1-induced vasodilatation. Preincubation with BQ-485 (10 76 M) or BQ-123 (3610 76 ) (ET A -receptor antagonist) signi®cantly augmented the ET-1-induced vasodilatation in control mesenteric arterial beds, but not that in beds from diabetic rats. 5 These results demonstrate that marked increases not only in plasma glucose, but also in plasma ET-1 occur in STZ-induced diabetic rats. We suggest that the decreased contractile response and the increased vasodilator response of the mesenteric arterial bed to ET-1 may both be due to desensitization of ET A receptors, though ET B receptors may also be desensitized. This desensitization may result from the elevation of the plasma ET-1 levels seen in STZ-induced diabetic rats.
Introduction
Endothelin-1 (ET-1), a vasoconstrictor peptide secreted from endothelial cells, is thought to play a role in a number of vascular diseases (Goto et al., 1996) . The endothelin family consists of three isoforms, namely ET-1, ET-2 and ET-3, and these have been shown to exert a wide variety of biological actions, all of which are thought to be mediated by ET receptors (Inoue et al., 1989) . Two distinct ET receptor subtypes, named ET A and ET B exist in mammalian tissues (Arai et al., 1990; Sakurai et al., 1990) . ET A and ET B receptors are located on the smooth muscle and the endothelium, respectively (Goto et al., 1996) . ET-1 constricts smooth muscle via the activation of ET A receptors (D'Orleans-Juste et al., 1993) and also leads to the release of endothelium-derived relaxing factor (EDRF) via the activation of the ET B receptors located on the endothelium (Warner, 1990) .
Plasma ET-1 levels in the diabetic state are increased (Takahashi et al., 1990; Collier et al., 1992) and the plasma concentration of big endothelin-1, the precursor of ET-1, was found to be elevated in patients with diabetes mellitus (Tsunoda et al., 1991) . In contrast to these ®ndings, no changes in plasma ET-1 levels and decreased levels of renal tissue ET-1 is found in the diabetic state (Shin et al., 1995) . In studies of an experimental model of diabetes, it has been found that the density of ET-1 receptors in cardiac tissue is reduced (Nayler et al., 1989) and the amount of ET-1 released from mesenteric arteries is increased (Takeda et al., 1991) . Furthermore, the contractile response of the aorta to ET-1 was attenuated in rats with streptozotocin (STZ)-induced diabetes (Fulton et al., 1991; Hodgson & King, 1992; Lieu & Reid, 1994; Tada et al., 1994) . The diabetic microcirculation is impaired responses to ET-1 and ET-3 (Lawrence & Brain, 1992) , and although the initial hindquarters vasodilatation induced with ET-1 are not dierent in STZ-treated and control rats, the subsequent renal and mesenteric vasoconstrictions are greater in the former (Ki et al., 1991) . In addition, exposure of endothelial cells to a high glucose concentration has been found to enhance ET-1 secretion (Yamauchi et al., 1990; Hattori et al., 1991) .
The aim of the present study was to examine whether the vasoactive actions of ET-1 are altered in resistance arteries, such as the mesenteric arterial bed, in STZ-induced diabetic rats. Hence, we investigated the eects of ET-1 or its analogue on isolated perfused mesenteric arterial beds taken from STZinduced diabetic rats.
Radioimmunoassay of ET-1
Plasma samples taken 10 weeks after injection of STZ or buer were extracted with Amprep C2 columns (Amersham International plc., Buckinghamshire, U.K.) following Amprep activation by 2 ml of 100% methanol and then 2 ml water. One millilitre of each plasma sample was acidi®ed with 0.25 ml 2 M HCl, centrifuged at 10000 g for 5 min at room temperature and loaded onto the column. The column was washed with 5 ml of 0.1% tri¯uoroacetic acid (TFA). Immunoreactive-endothelin was eluted with 2 ml of 80% acetonitrile/water containing 0.1% TFA. Then, the eluate was dried down under nitrogen and the resulting pellet reconstituted in assay buer (0.02 M borate buer pH 7.4 containing 0.1% sodium azide).
The concentration of ET-1 in the eluate of plasma samples was determined by radioimmunoassay by use of commercially available kits (endothelin 1-21 speci®c 125 assay system, Amersham International plc., Buckinghamshire, U.K.).
Preparation of the perfused mesenteric arterial bed
Ten weeks after treatment with STZ or buer, rats were anaesthetized with ether and then given an intravenous injection of 1000 units kg 71 heparin. Following decapitation under anaesthesia, a midline incision was made and the mesenteric arterial bed rapidly dissected out and placed in a bath of modi®ed Krebs-Henseleit solution (KHS, composition in mM: NaCl 118.0, KCl 4.7, NaHCO 3 25.0, CaCl 2 1.8, NaH 2 PO 4 1.2, MgSO 4 1.2, dextrose 11.0 and 0.25% bovine serum albumin). The mesenteric artery and vein were tied o near the caecum and the remaining intestinal wall. The mesenteric arterial bed was perfused by the method described by McGregor (1965) , with various modi®cations previously described by us (Kamata et al., 1989c; Kamata & Makino, 1997; Abiru et al., 1993a) . Brie¯y, the method used was as follows: warm (378C), oxygenated (95% O 2 -5% CO 2 ) KHS was pumped into the mesenteric arterial bed, by a peristaltic pump operating at a rate of 5 ml min 71 , through a cannula inserted into the superior mesenteric artery. Vascular responses were detected as changes in perfusion pressure, which was monitored continuously via a pressure transducer (Nihon Kohden, Model AP2001, Tokyo, Japan) and recorded on a pen recorder. Following a 60 min equilibration period, the perfusion circuit was transformed into a closed system by collecting the perfusate in a second bath and from there recirculating it through the mesenteric arterial bed. The total volume of the closed system was 50 ml and agents were administered via the second bath. The drug doses quoted represent the ®nal concentration in this system. After equilibration, the mesentery preparation was constricted by perfusion with a solution containing 4610 76 to 3610 75 M methoxamine, which resulted in a perfusion pressure of between 120 ± 140 mmHg. It was then maximally relaxed with a perfusion solution containing 10 76 M acetylcholine (ACh), a response which con®rmed the integrity of the endothelium in our preparation. The mesenteric arterial bed was completely relaxed after exposure to 10 76 M ACh. Drug-induced relaxation was expressed as a percentage of the increase in perfusion pressure induced by an equieective concentration of 
+ (60 mM) and 10 75 M indomethacin on the agonistinduced responses in the mesenteric arterial bed, the mesentery was incubated in the appropriate solution for 30 min before the addition of ET-1. To exclude the involvement of endothelium-derived hyperpolarizing factor (EDHF), some experiments were performed in which the mesenteric preparation was depolarized with isotonic high K + (60 mM) in the presence of nicardipine (10 77 M) before being constricted. Each preparation was used to test only one antagonist or isotonic high K + medium. In some experiments, the mesenteric preparation was perfused with Triton X-100 for 1 min to remove functionally the endothelial cells lining the resistance vessels. This treatment reduced the ACh (10 76 M)-induced vasodilatation by more than 90% without reducing the contractile eects of methoxamine. ]-endothelin-1 (8-21) (IRL1620) were purchased from Peptide Institute, Inc. (Osaka, Japan). 
Statistics
Data are presented as the mean+s.e.mean. In some experiments, statistical dierences were determined by Dunnet's test for multiple comparison, after a one-way analysis of variance, and a probability level of P50.05 was regarded as signi®cant. Statistical comparison between concentration-response curves was determined by two-way ANOVA with Bonferroni correction performed post-hoc to correct multiple comparison. A P50.05 was considered signi®cant.
Results

Plasma immunoreactive ET-1 concentration in controls and diabetic animals
The plasma glucose level in diabetic animals was approximately four times that seen in the controls. The plasma immunoreactive ET-1 level was also signi®cantly elevated in the diabetic rats (controls: 3.43+0.33 fmol 100 ml 71 ; diabetes: 5.82+0.77 fmol 100 ml 71 ( Figure 1 ).
Vasoconstrictor responses to ET-1
Cumulative concentration-response curves for the vasoconstriction induced by ET-1 (10 710 to 10 76 M) were obtained in perfused mesenteric arterial beds from both controls and diabetic rats (Figure 2) . The maximum response of the mesentery to ET-1 was signi®cantly reduced in STZ-induced diabetic rats. pEC 50 (-log EC 50 ) values for ET-1 were 8.8+0.1 M (n=11) and 7.2+0.2 M (n=12, P50.001), in controls and diabetes, respectively. When similar experiments were performed in the presence of the nitric oxide synthase (NOS) inhibitor, L-NOARG (10 74 M), ET-1-induced vasoconstrictions were slightly increased in diabetic or control rats, respectively (Figure 2 ). pEC 50 values for ET-1 in the presence of L-NOARG (10 74 M) were 9.2+0.1 M (n=9) and 7.0+0.1 M (n=7, P50.001), in controls and diabetes.
As shown in Figure 3a , vasoconstriction induced by ET-1 (10 711 to 10 77 M) was signi®cantly enhanced by L-NOARG (10 74 M) plus tetraethylammonium (TEA) (10 mM), whereas TEA (10 mM) or indomethacin ( vasoconstriction to the right. Surprisingly, ET-1-induced vasoconstriction was signi®cantly reduced in the endothelialdenuded preparation from control rats (Figure 3a) . In contrast, the dose-response curve for the ET-1-induced vasoconstriction was shifted to the left in STZ-induced diabetic rats (Figure 3b) . Treatment of the mesentery with TEA (10 mM), L-NOARG (10 74 M) plus TEA (10 mM), indomethacin (10 75 M) or BQ-788 (10 76 M) had no eect on ET-1-induced vasoconstriction in diabetes (Figure 3b ).
Vasodilator responses to IRL-1620
Cumulative concentration-response curves for the vasodilatation induced by the ET B -receptor agonist, IRL-1620 (10 710 to 10 76 M) were obtained in mesenteric arterial beds from controls and diabetic rats (Figure 4) (Figure 5b ).
Eects of various agents on the vasodilatation induced by ET-1
ET-1 (10 78 M) caused a transient vasodilatation followed by a marked vasoconstriction in the mesenteric arterial bed preconstricted with methoxamine (4610 76 to 3610 75 M) ( Figure 6 ). The maximum vasodilatation evoked by ET-1 in the controls (31.5+1.9%, n=6) was signi®cantly smaller than that evoked in the STZ-induced diabetic rats (62.0+6.4%, n=5, P50.001). By contrast, the maximum vasoconstriction in the controls (185.5+33.3%, n=6) was signi®cantly larger than that seen in STZ-induced diabetic rats (70.4+26.1%, n=5, P50.05).
Removal of endothelial cells by perfusion with Triton X-100 for 60 s almost abolished the ET-1-induced vasodilatation in both age-matched controls and STZ-induced diabetic rats (data not shown). Preincubation with BQ-788 (10 76 M) (ET Breceptor antagonist) also abolished the ET-1-induced vasodilatation in both age-matched controls and STZ-induced diabetic rats ( signi®cantly augmented the ET-1-induced vasodilatation in the age-matched controls but not in STZ-induced diabetic rats ( Figure 7) .
Treatment of the mesentery with 10 74 M L-NOARG signi®cantly decreased the ET-1-induced vasodilatation, the percentage inhibition being signi®cantly greater in the controls than in the STZ-induced diabetic rats (`untreated' response reduced in controls by 59.6+2.9% and in diabetic rats by 27.9+6.7%, P50.01). To exclude the involvement of EDHF in the ET-1-induced vasodilatation, the mesentery was depolarized with isotonic high K + solution (60 mM) in the presence of nicardipine (10 77 M); the mesenteric arterial bed was then contracted with methoxamine (4610 76 to 3610 75 M). Under these conditions, the ET-1-induced vasodilatation was signi®cantly reduced, the percentage inhibition being signi®cantly greater in the STZ-induced diabetic rats than in the controls (`untreated' response reduced in controls by 46.1+15.3% and in diabetic rats by 91.3+3.4%, P50.05). Incubating the mesentery with 10 75 M indomethacin signi®cantly decreased the ET-1-induced vasodilatation, extent of the inhibition being almost the same in the controls as in the STZ-induced diabetic rats (`untreated' response reduced in controls by 54.0+8.4% and in diabetic rats by 52.6+6.4%) (Figure 8 ).
Discussion
The main conclusions from the present study are that the plasma ET-1 level is signi®cantly higher in STZ-induced diabetic rats than in age-matched controls and that the contractile response to ET-1, via ET A receptors, and the vasodilator response, via ET B receptors were both desensitized. Moreover, the relative contributions made by the various endothelium-derived relaxing factors (EDRFs) to the ET-1-induced vasodilatation were dierent in the diabetic state than in non-diabetic state.
The contractile response of the mesenteric arterial bed to ET-1 was signi®cantly attenuated in the diabetic state. It has also been shown that responsiveness to ET-1 was attenuated in thoracic aortae isolated from diabetic rats 2 weeks after STZ treatment (Fulton et al., 1991) or 8 weeks after (Tada et al., 1994) . However, no signi®cant reduction was found in the response to noradrenaline of thoracic aortae isolated from 2-week STZ-diabetic rats (Fulton et al., 1991) . These results imply that the changes in responsiveness due to diabetes may vary depending on the diabetic period, the tissues studied and the type of response examined. The vasoconstrictor action of ET-1 has been shown to be exerted primarily via an increase in intracellular calcium (Hirata et al., 1988b) . Interestingly, Fulton et al. (1991) showed that in diabetes there may be, at least under some circumstances, an impairment of the mobilization of intracellular calcium stores. Moreover, an elevation of ET-1 levels may result in a homologous down-regulation of its receptors (Hirata et al., 1988a; Nayler et al., 1989; Miasiro & Paiva, 1990 ). It will need to be determined by further research whether the decrease in the contractile response to ET-1 is mediated by the former eect or by the latter. ET-1 stimulates the release of nitric oxide (NO) (Warner et al., 1989b) . Indeed, in the present study L-NOARG, an inhibitor of NO synthase, slightly but signi®cantly increased the vasoconstrictor responses to ET-1 in controls. This suggests that NO-synthase products play an important role in modifying the constrictor eects of ET-1 in the rat mesenteric arterial bed.
The ET B receptor, which occurs predominantly on endothelial cells, mediates vasodilatation through the generation of endothelium derived relaxing factors (EDRFs) and prostacyclin (Thiemermann et al., 1988; De Nucci et al., 1988; Wright & Fozard, 1988; Warner et al., 1989a; Luscher et al., 1993) . In the present study, we found that the vasodilatation induced by IRL-1620, an ET B -receptor agonist, was signi®cantly attenuated in STZ-induced diabetic rats. However, there was no signi®cant dierence between controls and diabetic rats in terms of EC 50 values. In STZinduced diabetic rats, the density of ET-1 receptors is reduced in cardiac tissue (Nayler et al., 1989) . As both the contractile response via ET A stimulation and the vasodilator response via ET B stimulation were reduced in our diabetic rats, it is likely that the attenuation of responsiveness to ET-1 is the result of a general decrease in the number of ETreceptors.
ET-1 caused a transient vasodilatation in the mesenteric arterial bed when it had been preconstricted with methoxamine. This response was abolished by removal of the endothelium and by pretreatment with BQ-788, an antagonist of the ET B receptor. Thus, in the mesenteric bed, ET-1-induced vasodilatation seems to be mediated by ET B receptors localized on the endothelium.
The relaxation responses of aortic strips to endotheliumdependent agents are decreased in STZ-induced diabetic rats (Oyama et al., 1986; Pieper & Gress, 1988; Kamata et al., 1989a, b; Tomlinson et al., 1992; Abiru et al., 1993b; Poston & Taylor, 1995) . Surprisingly, we found that the vasodilator response of the mesenteric arterial bed to ET-1 was signi®cantly increased in diabetes. Furthermore, preincubating the mesentery with BQ-485, an antagonist of the ET A receptor, or BQ-123, another antagonist of the ET A receptor, signi®cantly augmented the ET-1-induced vasodilatation in the controls, but not in STZ-induced diabetic rats. It is likely, therefore, that an attenuation of the contractile response to ET-1, which is mediated by the ET A receptor, underlies the enhancement of the ET-1-induced vasodilatation that we saw in diabetic rats.
Treatment of the mesentery with L-NOARG signi®cantly decreased the ET-1-induced vasodilatation, the percentage reduction being signi®cantly greater in the controls than in STZ-induced diabetic rats. By contrast, in a mesenteric arterial bed already depolarized with K + , the ET-1-induced vasodilatation was signi®cantly decreased, the percentage reduction being signi®cantly greater in STZ-induced diabetic rats than in the controls. Treatment of the mesentery with indomethacin signi®cantly decreased the ET-1-induced vasodilatation to a similar degree in controls and STZ-induced diabetic rats. These results suggest that the enhancement of the ET-1-induced vasodilatation of the mesentery that was seen in the diabetic state may be due to an attenuation of ET A -receptormediated vasoconstriction and to an increased release of EDHF.
It is surprising that the ET-1-induced vasoconstriction was signi®cantly reduced in the endothelial-denuded preparation in control rats and was signi®cantly increased in diabetic rats. While the ET-1-induced vasoconstriction was markedly inhibited by the detergent, Triton X-100, this may not be due to the destruction of ET-1 receptors. If Triton X-100 destroys the ET-1 receptors, the ET-1-induced vasoconstriction should be decreased in the diabetic rats. This was not the case. The precise mechanisms of ET-1-induced vasoconstriction will be necessary to understand these data more fully.
In conclusion, we found marked increases not only in plasma glucose but also in the plasma ET-1 level in STZinduced diabetic rats. The decreased contractile response and the increased vasodilator response of the mesenteric arterial bed to ET-1 seen in diabetic rats may be due primarily to a desensitization of ET A receptors, though ET B receptors are also desensitized. This desensitization may be a consequence of the elevation in the plasma endothelin-1 level seen in STZinduced diabetic rats.
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